EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Shyam Sundar, Krishna Pandey, Dinesh Mondal, Major Madhukar, Roshan Kamal Topno, Ashish Kumar, Vinod Kumar, Deepak Kumar Verma, Jaya Chakravarty, Rahul Chaubey, Poonam Kumari, Md Utba Rashid und 9 weitere

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012242 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Shyam Sundar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Kala-azar Medical Research Center (KARMC), Muzaffarpur, India. Hauptthemen laut MEDLINE: Amphotericin B, Phosphorylcholine, Antiprotozoal Agents, Leishmaniasis, Visceral. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Française de Développement, WHO-TDR, Direktion für Entwicklung und Zusammenarbeit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefosine (MF), is low and ocular toxicity has been observed with this exposure period. We assessed the safety and efficacy of two shorter-course treatments: liposomal amphotericin B (LAmB) alone and combined with MF. Methodology/Principal findings An open-label, phase II, randomized, parallel-arm, non-comparative trial was conducted in patients with parasitologically confirmed PKDL, 6 to ≤60 years. Patients were assigned to 20 mg/kg LAmB (total dose, in five injections over 15 days) alone or combined with allometric MF (3 weeks). The primary endpoint was definitive cure at 12 months, defined as complete resolution of papular and nodular lesions and >80% re-pigmentation of macular lesions. Definitive cure at 24 months was a secondary efficacy endpoint. 118/126 patients completed the trial. Definitive cure at 12 months was observed in 29% (18/63) patients receiving LAmB and 30% (19/63) receiving LAmB/MF (mITT), increasing to 58% and 66%, respectively, at 24 months. Most lesions had resolved/improved at 12 and 24 months for patients receiving LAmB (90%, 83%) and LAmB/MF (85%, 88%) by qualitative assessment. One death, unrelated to study drugs, was reported; no study drug-related serious adverse events were observed. The most frequent adverse drug reactions were MF-related vomiting and nausea, and LAmB-related hypokalaemia and infusion reactions. Most adverse events were mild; no ocular adverse events occurred. Conclusions/Significance Both regimens are suitably safe and efficacious alternatives to long-course MF for PKDL in South Asia.

Trial registration

CTRI/2017/04/008421 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BPhosphorylcholineAntiprotozoal AgentsLeishmaniasis, VisceralLeishmaniasis, CutaneousHumansBangladeshMaleAdultAdolescentFemaleMiddle AgedYoung AdultChildIndiaTreatment OutcomeDrug Therapy, Combination

Substanzen

miltefosineAmphotericin BPhosphorylcholineliposomal amphotericin BAntiprotozoal Agents

Autor:innen und Institutionen

  • Kala-azar Medical Research Center (KARMC), Muzaffarpur, India.
  • Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
  • ICMR-Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India.
  • International Centre for Diarrhoeal Disease Research, (icddrb,b), Dhaka, Bangladesh.
  • Drugs for Neglected Diseases initiative, New Delhi, India.
  • Drugs for Neglected Diseases initiative, Rio de Janeiro, Brazil.

ORCID-Profile: Fabiana Alves

Förderung

  • Agence Française de Développement
  • WHO-TDR
  • Direktion für Entwicklung und Zusammenarbeit
  • Ministerie van Buitenlandse Zaken
  • Médecins Sans Frontières
  • UK aid

Zitieren

APA

Sundar, S., Pandey, K., Mondal, D., Madhukar, M., Kamal Topno, R., Kumar, A., Kumar, V., Kumar Verma, D., Chakravarty, J., Chaubey, R., Kumari, P., Rashid, M. U., Maruf, S., Ghosh, P., Raja, S., Rode, J., den Boer, M., Das, P., Alvar, J., …, & Alves, F. (2024). A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012242

Vancouver

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R, Kumar A, et al. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012242

BibTeX
@article{Sundar2024,
  author = {Sundar, Shyam and Pandey, Krishna and Mondal, Dinesh and Madhukar, Major and Kamal Topno, Roshan and Kumar, Ashish and Kumar, Vinod and Kumar Verma, Deepak and Chakravarty, Jaya and Chaubey, Rahul and Kumari, Poonam and Rashid, Md Utba and Maruf, Shomik and Ghosh, Prakash and Raja, Sheeraz and Rode, Joelle and den Boer, Margriet and Das, Pradeep and Alvar, Jorge and Rijal, Suman and Alves, Fabiana},
  title = {A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012242}
}
Kostenlos starten →